Please login to the form below

Not currently logged in
Email:
Password:

Aimovig

This page shows the latest Aimovig news and features for those working in and with pharma, biotech and healthcare.

Amgen and Novartis migraine drug hits the mark again

Amgen and Novartis migraine drug hits the mark again

Amgen and Novartis migraine drug hits the mark again. Aimovig will become the first CGRP receptor-targeting drug if it reaches market. ... The two partners maintain that Aimovig is different to its rivals because they target CGRP itself, as opposed to

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics